Beginning of Effective and Safe Treatment in Immunoglobulin A-1 Nephropathy-1

Summary

Immunoglobulin A nephropathy (IgAN) is the most common glomerulonephritis worldwide. IgAN is progressive, particularly when patients have a significant proteinuria (proteinuria \>1g/g creatinine), impaired kidney function, or elevated blood pressure. In 10 years, nearly 20-40% of these IgAN patients progress to end-stage renal disease (ESRD). Early IgAN is tentatively defined when proteinuria is insignificant and kidney function and blood pressure are normal. Patients with early IgAN rarely progress to ESRD. However, 30-40% of patients with early IgAN ultimately developed a significant proteinuria and hypertension in 10 years. Therefore, earlier intervention may be needed if it can prevent the development of a significant proteinuria and hypertension. Since angiotensin ll receptor blocker (ARB) is drug of choice in reducing proteinuria and controlling blood pressure, the investigators hypothesized that early introduction of ARB may be beneficial in preventing the significant proteinuria development in early IgAN patients. To prove the hypothesis, the investigators plan the current interventional study.

Conditions

• Glomerulonephritis, Immunoglobulin A (IgA)

Interventions

DRUG

Losartan group

Losartan 50 mg daily

DRUG

Placebo group

Placebo 1 pill daily

Sponsors & Collaborators

• The Catholic University of Korea

  collaborator OTHER

• Kyung Hee University Hospital at Gangdong

  collaborator OTHER

• Kyungpook National University Hospital

  collaborator OTHER

• Korea University Guro Hospital

  collaborator OTHER

• SMG-SNU Boramae Medical Center

  collaborator OTHER

• Seoul National University Bundang Hospital

  collaborator OTHER

• Seoul National University Hospital

  collaborator OTHER

• Ajou University School of Medicine

  collaborator OTHER

• Pusan National University Yangsan Hospital

  collaborator OTHER

• Severance Hospital

  collaborator OTHER

• Eulji General Hospital

  collaborator OTHER

• National Health Insurance Service Ilsan Hospital

  collaborator OTHER

• Chonnam National University Hospital

  collaborator OTHER

• Chonbuk National University Hospital

  collaborator OTHER

• Kangdong Sacred Heart Hospital

  collaborator OTHER

• Hallym University Medical Center

  collaborator OTHER

• Gangnam Severance Hospital

  collaborator OTHER

• Ewha Womans University

  lead OTHER

Principal Investigators

• Dong-Ryeol Ryu, Professor · Ewha Womans University

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Model

PARALLEL

Eligibility

Min Age

19 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2018-01-30

Primary Completion

2021-12-31

Completion

2021-12-31